10x Genomics, INC

10x Genomics stockholders re-elected three Class I directors and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

10x Genomics reported Q1 2026 results with a 3% revenue decrease year-over-year, but excluding one-time items, revenue grew 9%, driven by new product launches and strategic partnerships.

10x Genomics reported significantly reduced net and operating losses for Q4 and full year 2025, alongside a strong cash position and new strategic partnerships, while forecasting modest revenue growth for 2026.

10x Genomics announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, showing mixed growth across its single cell and spatial biology segments.

10x Genomics announced the retirement of its Chief Legal Officer, Eric S. Whitaker, effective January 1, 2026, with Dr. Randy Wu appointed as his successor.

10x Genomics reported a 2% sequential revenue increase excluding one-time items, alongside a significant boost in cash and cash equivalents for Q3 2025, despite a year-over-year revenue decline.

10x Genomics, Inc. reported a significantly reduced net loss for Q3 2025 and the nine months ended September 30, 2025, driven by substantial license and royalty revenue from patent settlements and effective cost reduction strategies, alongside a strategic acquisition.

10x Genomics reported a net income of $34.5 million in Q2 2025, driven by significant patent litigation settlements, and announced the acquisition of Scale Biosciences.

10x Genomics' Q1 2025 revenue shows a mixed performance with a decrease in product sales offset by licensing revenue from a settlement with Vizgen.

10x Genomics' Q3 2024 results show a slight revenue decrease and a reduced net loss compared to the same period last year, while the company continues to navigate complex patent litigation.

10x Genomics' second quarter results show a slight revenue increase but a continued net loss, alongside ongoing legal proceedings and strategic shifts.

10x Genomics saw a 5% increase in revenue year-over-year in Q1 2024, driven by strong growth in spatial instrument sales, though consumables revenue declined slightly.

10x Genomics' 2024 revenue slightly decreased by 1% year-over-year, accompanied by a reduced net loss, as the company navigated strategic changes and ongoing intellectual property litigation.

10x Genomics, a life sciences technology company, announced a 20% year-over-year revenue increase to $618.7 million for 2023, while also reporting a net loss of $255.1 million.

Serge Saxonov, CEO of 10x Genomics, has reported the sale of Class A Common Stock valued at over $25 million through a pre-arranged trading plan.

10x Genomics Director Shehnaaz Suliman reported the sale of Class A Common Stock under a pre-arranged trading plan.

Director Sarah Teichmann was granted 8,829 restricted stock units in 10x Genomics, Inc. as part of standard equity compensation.

Director Shehnaaz Suliman was granted 8,829 restricted stock units as part of her compensation package with 10x Genomics.

Director John R. Stuelpnagel was granted 8,829 restricted stock units as part of his compensation package with 10x Genomics.

Director Kimberly J. Popovits was granted 8,829 restricted stock units as part of her compensation package with 10x Genomics.

10x Genomics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 4, 2026.

10x Genomics, Inc. has filed a definitive proxy statement with the SEC.

10x Genomics will hold its 2025 Annual Meeting of Stockholders virtually on June 3, 2025, to vote on director elections, auditor ratification, and executive compensation.

10x Genomics is seeking shareholder approval to amend its bylaws, allowing the Board to make changes without requiring a shareholder vote, a practice aligned with the vast majority of public companies.

10x Genomics has filed a definitive proxy statement with the SEC.

10x Genomics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 11, 2024, including proposals for director election, auditor ratification, bylaw amendment, and executive compensation advisory vote.

Vanguard Capital Management reports beneficial ownership of 6,166,597 shares, representing 5.24% of 10X Genomics Inc.'s common stock, as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.93% in 10X Genomics Inc. common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in 10X Genomics Inc. following an internal organizational realignment.

The Vanguard Group has filed an amended Schedule 13G, indicating it no longer holds a beneficial ownership stake in 10X Genomics Inc.

FMR LLC and Abigail P. Johnson reported a beneficial ownership of 15.6% of 10x Genomics, Inc.'s Class A Common Stock as of February 27, 2026.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 10.8% of 10x Genomics, Inc.'s Class A Common Stock as of December 31, 2025.